SCHEMBL3591330

SCHEMBL3591330

C=CCOC(=O)c1cnc(Cl)nc1[N+](C)(C)C1CCC2(CC1)CC2

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.34
ALDH1A1 P00352 2/20 0.32
TSHR P16473 2/20 0.32
HSD17B10 Q99714 2/20 0.32
PKM P14618 1/20 0.32
CACNA1D Q01668 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
KMT2A Q03164 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
ALOX12 P18054 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590094 0.85 CTSS (0.37) CYP3A4ALDH1A1TSHRHSD17B10KDM4E
SCHEMBL3601980 0.78 CYP3A4 (0.36) CYP3A4ALDH1A1TSHRHSD17B10
SCHEMBL3591329 0.77 SYK (0.35) CYP3A4ALDH1A1TSHRHSD17B10RAB9A
SCHEMBL3591331 0.77 CYP3A4 (0.33) CYP3A4ALDH1A1TSHRHSD17B10RAB9A
SCHEMBL3601469 0.71 CYP3A4 (0.50) CYP3A4ALDH1A1TSHRHSD17B10KDM4E
SCHEMBL3591335 0.67 SYK (0.34) CYP3A4ALDH1A1
SCHEMBL3595213 0.66 CTSS (0.44) CYP3A4
SCHEMBL23974077 0.65 NR2F2 (0.51) ALDH1A1KDM4EMEN1LMNAMAPT
SCHEMBL29761462 0.65 NR2F2 (0.51) ALDH1A1KDM4EMEN1LMNAMAPT
SCHEMBL3590091 0.65 CTSS (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7704996-B2 Compounds and compositions useful as cathepsin S inhibitors NOVARTIS AG (CH) 2010-04-27 US disclosed
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2009-02-19 US disclosed
EP-1781623-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS Novartis AG (CH) 2007-05-09 EP disclosed
WO-2006018284-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS CTSS, CTSZ, CTSF CYP3A4 2233/4885ALDH1A1 4107/4885TSHR 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.